Mepolizumab in children and adolescents with severe eosinophilic asthma not eligible for omalizumab: a single Center experience

References

• Dupilumab (Dupixent). Scottish medicines consortium. 2021. https://www.scottishmedicines.org.uk/medicines-advice/dupilumab-dupixent-full-smc2317/
   Google Scholar
• Dupilumab for treating severe asthma with type 2 inflammation: Guidance. NICE. 2021. https://www.nice.org.uk/guidance/ta751/chapter/1-Recommendations
   Google Scholar
• Sorkness CA, Wildfire JJ, Calatroni A, et al. Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. J Allergy Clin Immumol Pract. 2013;160:102–110.
   Google Scholar
• Kallieri M, Papaioannou AI, Papathanasiou E, Ntontsi P, Papiris S, Loukides S. Predictors of response to therapy with omalizumab in patients with severe allergic asthma – a real life study. Postgrad Med. 2017;129(6):598–604. doi:10.1080/00325481.2017.1321945.
   PubMed Web of Science ®Google Scholar
• Scottish Medicine Consortium 2016. Mepolizumab 100mg powder for solution for injection (NucalaVR). SMC No. (1149/16).
   Google Scholar
• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention: GINA Main Report 2022. 2022. https://ginasthma.org/wp-content/uploads/2022/07/GINA-Main-Report-2022-FINAL-22-07-01-WMS.pdf
   Google Scholar
• Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X.
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, Humbert M, Katz LE, Keene ON, Yancey SW, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290.
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, SIRIUS Investigators Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa1403291.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline. European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma. London, UK: GlaxoSmithKline; 2018. https://www.gsk.com/en-gb/ media/press-releases/european-commission-approvesnucala-mepolizumab-for-the-treatment-of-children-withsevere-asthma/
   Google Scholar
• Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J. Long term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336–1342.e7. e1337 doi:10.1016/j.jaci.2019.08.005.
   PubMed Web of Science ®Google Scholar
• Gupta A, Pouliquen I, Austin D, Price RG, Kempsford R, Steinfeld J, Bradford ES, Yancey SW. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019;54(12):1957–1967. doi:10.1002/ppul.24508.
   PubMed Web of Science ®Google Scholar
• Weir E, Paton JY. Mepolizumab in adolescents with severe eosinophilic asthma not eligible for omalizumab: one center’s early clinical experience. J Asthma. 2020;57(5):521–524. doi:10.1080/02770903.2019.1579833.
   PubMed Web of Science ®Google Scholar
• Ullmann N, Peri F, Florio O, Porcaro F, Profeti E, Onofri A, Cutrera R. Severe Pediatric Asthma Therapy: mepolizumab. Front Pediatr. 2022;10:920066. doi:10.3389/fped.2022.920066.
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, Schatz M, Li JT, Marcus P, Murray JJ, Pendergraft TB. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113(1):59–65. doi:10.1016/j.jaci.2003.09.008.
   PubMed Web of Science ®Google Scholar
• Scottish Index of Multiple Deprivation 2020v2. 2020. https://www.gov.scot/collections/scottish-index-of-multiple-deprivation-2020/#revisionnotice
   Google Scholar
• Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CPM, Gustafsson P, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.00034805.
   PubMed Web of Science ®Google Scholar
• Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CPM, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522. doi:10.1183/09031936.05.00035005.
   PubMed Web of Science ®Google Scholar
• American Thoracic Society; European Respiratory Society. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST.
   PubMed Web of Science ®Google Scholar
• Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MSM, Zheng J, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343. doi:10.1183/09031936.00080312.
   PubMed Web of Science ®Google Scholar
• Malinovschi A, Fonseca JA, Jacinto T, Alving K, Janson C. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013;132(4):821–827.e5. doi:10.1016/j.jaci.2013.06.007.
   PubMed Web of Science ®Google Scholar
• Szefler SJ, Goldstein S, Vogelberg C, Bensch GW, Given J, Jugovic B, Engel M, Moroni-Zentgraf PM, Sigmund R, Hamelmann EH, et al. Forced Expiratory Flow (FEF25-75%) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: a Post Hoc Analysis. Pulm Ther. 2020;6(2):151–158. doi:10.1007/s41030-020-00117-6.
   PubMedGoogle Scholar
• Chan R, Lipworth BJ. Determinants of asthma control and exacerbations in moderate to severe asthma. J Allergy Clin Immunol Pract. 2022;10(10):2758–2760.e1. doi:10.1016/j.jaip.2022.06.042.
   PubMed Web of Science ®Google Scholar
• Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, Gill MA, Stokes J, Liu AH, Gruchalla RS, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10351):502–511. doi:10.1016/S0140-6736(22)01198-9.
   PubMed Web of Science ®Google Scholar
• Matucci A, Vivarelli E, Bormioli S, Francesca N, Chiccoli F, Valentina M, Francesca G, Oliviero R, Parronchi P, Vultaggio A, et al. Long-term retention rate of mepolizumab treatment in severe asthma: a 36-months real-life experience. J Asthma. 2023;60(1):158–166. doi:10.1080/02770903.2022.2036754.
   PubMed Web of Science ®Google Scholar
• Liu MC, Bel EH, Kornmann O, et al. Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET. ERJ Open Res. 2022;8(1):00419–02021. doi:10.1183/23120541.00419-2021.
   PubMedGoogle Scholar
• Jackson D, Shackshaft L, Green L, et al. The relationship between fractional exhaled nitric oxide and asthma symptom scores in patients on mepolizumab. European Respiratory Journal 2019. 54(63):PA2623. doi:10.1183/13993003.congress-2019.PA2623.
   Google Scholar
• European Medicines Agency. Nucala (mepolizumab) - Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdf
   Google Scholar
• Redmond C, Akinoso-Imran AQ, Heaney LG, Sheikh A, Kee F, Busby J. Socioeconomic disparities in asthma health care utilization, exacerbations, and mortality: A systematic review and meta-analysis. J Allergy Clin Immunol. 2022;149(5):1617–1627. doi:10.1016/j.jaci.2021.10.007.
   PubMed Web of Science ®Google Scholar
• Mazumdar S, Ghosh S, Mukherjee S. Non-adherence to asthma medications: relation to socio-economic status and asthma education. European Respiratory Journal. 2015;46: OA4792. doi:10.1183/13993003.congress-2015.OA4792.
   Web of Science ®Google Scholar
• Hadaway V, Parker R, Whitehouse A. Housing and health – impact of mould on children with asthma. European Respiratory Journal. 2022;60:2546. doi:10.1183/13993003.congress-2022.2546.
   Web of Science ®Google Scholar
• Lejeune S, Sauvere M, Chagnon F, et al. Impact of moisture/mould exposure on asthma control in children: the Champiasthma Study. Europ Resp J. 2022;60:2058. doi:10.1183/13993003.congress-2022.2058.
   Web of Science ®Google Scholar